Status:

COMPLETED

Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans

Lead Sponsor:

Tufts University

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

40+ years

Phase:

PHASE2

Brief Summary

North American blacks tend to have low blood levels of vitamin D because pigmentation blocks vitamin D production in the skin. They also have higher rates of developing type 2 diabetes and higher rate...

Eligibility Criteria

Inclusion

  • African-American by self designation
  • Glucose intolerance defined as FPG ≥ 100 mg/dl or A1c ≥ 5.8%
  • BMI 25.0-39.9
  • Age 40 or older

Exclusion

  • Medical Conditions
  • Diabetes potentially requiring pharmacotherapy, defined as A1c \> 7%
  • Uncontrolled thyroid disease
  • Current parathyroid, liver or kidney disease
  • Renal stone within 5 years
  • Sarcoidosis, current pancreatitis, active tuberculosis, hemiplegia, gout
  • Inflammatory bowel disease, colostomy, malabsorption
  • Cancer other than basal cell skin cancer within 5 years
  • Uncontrolled arrhythmia in past year
  • Albinism or other condition associated with reduced skin pigmentation
  • Pregnancy over the last 1 year
  • Intent to become pregnant
  • Menopause onset within 1 year
  • Any other unstable medical condition Laboratory Tests
  • Fasting plasma glucose \< 100
  • Hemoglobin A1c \> 7%
  • Laboratory evidence of liver disease (e.g. AST \> 70 U/L or ALT \> 72 IU/L)
  • Laboratory evidence of kidney disease (e.g. estimated glomerular filtration rate \< 60 ml/min/1.73 m2).
  • Elevated spot urine calcium to creatinine ratio \> 0.38 mg/dl\*
  • Abnormal serum calcium (serum calcium \> 10.5 mg/dl)
  • Anemia (Hematocrit \< 36% in men, \<33% in women) Medications (use in past three months)
  • Estrogen or testosterone
  • Prescription vitamin D
  • Lithium
  • Oral corticosteroids
  • Anti-seizure medications
  • Unstable doses of psychotropics or phenothiazines
  • Cholestyramine Supplements (current use - may discontinue after screening)
  • Vitamin D supplements, cod liver oil, calcium supplements Other
  • Body mass index less \<25 or \> 39.9
  • Consumption of more than 14 alcoholic drinks per week
  • Inability to attend all three study visits as scheduled
  • Inability to provide written informed consent
  • age \< 40 years
  • not African-American (by self-designation)
  • Participation in another research intervention study
  • corresponds to a 24-hour urinary calcium excretion \> 400 mg

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2011

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00784511

Start Date

July 1 2008

End Date

February 1 2011

Last Update

November 14 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University

Boston, Massachusetts, United States, 02111